BioPlus Specialty Pharmacy Has Available Mavyret: the Newly FDA…


BioPlus Specialty Pharmacy

BioPlus Specialty Pharmacy (BioPlus), one of the nation’s leading innovative specialty pharmacies, announces that it can dispense Mavyret™ (glecaprevir/pibrentasvir) manufactured by AbbVie. Mavyret received FDA approval on August 3, 2017 as a once-daily treatment for chronic infection of genotypes 1-6 of the hepatitis C virus.

“For many years, our specialty pharmacy has been involved in treating patients with hepatitis C; one of the stand-out differences with this new medication is that Mavyret is pan-genotype, meaning it can be used by nearly all (95%) hepatitis C patients,” says Stephen Vogt, Pharm.D., President…



Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *